Busitema University Faculty of Health Sciences, Mbale Regional Referral Hospital, Mbale, Uganda.
Mbale Clinical Research Institute, Mbale, Uganda.
Am J Hematol. 2022 May;97(5):527-536. doi: 10.1002/ajh.26492. Epub 2022 Feb 16.
Sickle cell anemia (SCA) is common in sub-Saharan Africa where approximately 1% of births are affected. Severe anemia is a common cause for hospital admission within the region yet few studies have investigated the contribution made by SCA. The Transfusion and Treatment of severe anemia in African Children Trial (ISRCTN84086586) investigated various treatment strategies in 3983 children admitted with severe anemia (hemoglobin < 6.0 g/dl) based on two severity strata to four hospitals in Africa (three Uganda and one Malawi). Children with known-SCA were excluded from the uncomplicated stratum and capped at 25% in the complicated stratum. All participants were genotyped for SCA at trial completion. SCA was rare in Malawi (six patients overall), so here we focus on the participants recruited in Uganda. We present baseline characteristics by SCA status and propose an algorithm for identifying children with unknown-SCA. Overall, 430 (12%) and 608 (17%) of the 3483 Ugandan participants had known- or unknown-SCA, respectively. Children with SCA were less likely to be malaria-positive and more likely to have an affected sibling, have gross splenomegaly, or to have received a previous blood transfusion. Most outcomes, including mortality and readmission, were better in children with either known or unknown-SCA than non-SCA children. A simple algorithm based on seven admission criteria detected 73% of all children with unknown-SCA with a number needed to test to identify one new SCA case of only two. Our proposed algorithm offers an efficient and cost-effective approach to identifying children with unknown-SCA among all children admitted with severe anemia to African hospitals where screening is not widely available.
镰状细胞贫血症(SCA)在撒哈拉以南非洲很常见,大约 1%的新生儿受到影响。严重贫血是该地区住院的常见原因,但很少有研究调查 SCA 的贡献。在非洲进行的严重贫血症儿童输血和治疗试验(ISRCTN84086586)根据两个严重程度分层,在非洲的 4 家医院(乌干达 3 家,马拉维 1 家)对 3983 名患有严重贫血症(血红蛋白<6.0 g/dl)的儿童进行了各种治疗策略的调查。已知患有 SCA 的儿童被排除在简单分层之外,在复杂分层中最多占 25%。所有参与者在试验结束时都接受了 SCA 的基因分型。马拉维的 SCA 很罕见(总共 6 例患者),因此我们在这里重点关注在乌干达招募的参与者。我们根据 SCA 状况介绍了基线特征,并提出了一种用于识别未知-SCA 儿童的算法。总体而言,3483 名乌干达参与者中,有 430 名(12%)和 608 名(17%)分别患有已知或未知 SCA。患有 SCA 的儿童更有可能疟原虫阳性,更有可能有受影响的兄弟姐妹,有明显的脾肿大,或以前接受过输血。大多数结局,包括死亡率和再入院率,在患有已知或未知 SCA 的儿童中都优于非 SCA 儿童。基于七个入院标准的简单算法可以检测到所有未知 SCA 儿童的 73%,只需测试两次即可识别出一个新的 SCA 病例。我们提出的算法为在无法广泛进行筛查的非洲医院中,对所有因严重贫血住院的儿童中识别未知 SCA 儿童提供了一种高效且具有成本效益的方法。